Truin et al. recently reported in Annals of Oncology on the effect of adjuvant chemotherapy in postmenopausal women (aged 50-75 years) with invasive lobular (ILC) versus ductal (IDC) breast cancer using a very large nationwide cohort [1] . Patients with IDC receiving combined (endocrine (ET) and chemo (CT)) therapy had better overall survival compared with those receiving ET only. Combined treatment did not improve overall survival in ILC, which led the authors to conclude that there seems to be no benefit of adjuvant chemotherapy in patients with ILC who receive endocrine therapy.
We would like to provide those interested in this manuscript with some important remarks allowing us to conclude that the study from Truin should not be used as a proof to omit adjuvant chemotherapy in ILC:
(i) Truin et al. question the benefit of adjuvant chemotherapy in ILC based on the low response of ILC observed in the neoadjuvant setting [1] [2] [3] . We believe that this argument lacks strength since pathological complete remission has no prognostic value in ILC or luminal A breast cancer [4] . The majority (>80%) of ILC belong to the Luminal A subgroup indeed (own data) [5] . (ii) In retrospective analyses like Truin's study, there is a real chance that the observed outcome results from selection bias rather than from a treatment effect. Although multivariate analysis was carried out, several potentially important variables such as lymphovascular invasion, quantitative ER and/or PR status, HER2 status and 'amount' of lymph node invasion were not studied. (iii) The effect of chemotherapy in retrospective nonrandomized studies should better be measured by assessing the outcome variable it directly influences (distant metastasis) or subsequently influences (improved breast cancer specific survival). Studying overall survival can be problematic as it can be influenced by imbalance in the general health condition status (e.g. possibly more patients with comorbidity, frailty, limited general life expectancy in ET group (since patients were withheld CT) where patients could die more often from non-breast-cancer related causes).
We would like to support the third point of criticism using our own database (Table 1 ). We here demonstrate that breast cancer-specific death and distant metastatic recurrence is clearly higher in the ET + CT group, although the contrary is true when one would study overall death. 
